Oct 18, 2025
3 min read
New research shows that popular GLP-1 drugs like Ozempic can provide early clues about how quickly alcohol affects the body, with their surprising effects on cravings, addiction and reward.
The study: A preliminary study of the physical activity and cognitive function of GLP-1 receptor stress when using obese individuals.Photo credit: niksdope / shutterstock.com
In a preliminary human study published in Scientific Reports, researchers investigated whether glucagon-like peptide-1 receptor (GLP-1 AR) agonists, including semaglutide (Ozempic), can alter the body's physiological and psychological response to alcohol.
L’étude a utilisé les données de 20 participants adultes (21 ans et plus) (de juillet 2023 à mai 2024), dont la moitié ont reçu une dose d’entretien (minimum 4 semaines) d’AR GLP-1 (cas). Comme il ne s’agissait pas d’un essai randomisé, l’étude a comparé les participants prenant déjà des AR GLP-1 avec des témoins appariés n’utilisant pas ces médicaments.
The results of the study showed that participants who took GLP-1 RA had significantly slower increases in breath alcohol concentration and sensations of intoxication compared to the control group.These observations are consistent with a peripheral mechanism, possibly related to decreased gastric emptying, that may reduce the immediate effects of alcohol.
Glucagon as peptide 1 receatotor 1 glp-1.However, more than these targets, the growing number of animal studies and patient reports suggest that Glp-1 Ars reduces alcohol.
These findings have sparked intense scientific interest in understanding the mechanisms underlying these observations, with most studies focusing on determining where these drugs act primarily in the brain's reward center, like anti-addiction drugs like naltrexone, or whether they act through more physical peripheral mechanisms in the body.
An independent study on GLP-1 ARs showed that these drugs can slow gastric emptying.Since alcohol is primarily absorbed in the gut, not the intestines, slowing its absorption could theoretically blunt its effects, making the act of drinking less rewarding.
About the study
This study aims to fill this knowledge gap by confirming the role of GLP-1 AR in alcohol consumption and understanding the potential mechanisms underlying this interaction.She conducted a preliminary observational study of 20 adult participants (aged 21 and older) with a clinical diagnosis of obesity.
The registered participants were divided into two groups: an experimental group of 10 people received a stable portion of GLP-1 RAPRANDE
The research experiment involved a single session in a controlled "research lane" in which each participant consumed a carefully calculated amount of alcohol designed to achieve a target blood alcohol level.Over the next 60 minutes, the research team repeatedly measured the participants' blood alcohol concentration (BrAC) using a breathalyzer and asked them to rate their level of intoxication on a simple scale.
Blood glucose levels and Nausea measurements were also taken before and during the study, and statistical analysis lines were used using the bame package4).
consider the results
The results of this study revealed a delay in the results of alcoholism in cases compared to controls.In particular, the levels of BRAC in the old cohort increased more slowly than in the control, with differences observed in the first 20 groups.
After only 20 minutes of alcohol consumption, mean BrAC in the control group was more than twice that of the GLP-1 RA group (0.037 g/dL vs. 0.017 g/dL, p = 0.001).It also found that total cumulative alcohol exposure per hour was significantly lower in the medication group (p=0.008) compared to their control counterparts who did not take GLP-1 medication.
It was found that the experiences of the subjects of the participants reflect these objective results, the controls were significantly more mastotilin drunk than those who kept GLP1-Ra-RA.This complaint could not be explained by nausea, because both groups reported equal levels of nausea.The study ended with the Glip-1 Ra group before the start of the session (p = 0.03).
Blood sugar levels were measured before and after each drink, but there was no difference between the groups.
This study provides the first evidence consistent with the hypothesis that GLP-1 Ars modulates the body's response to alcohol in a potential way.Studies show that it is delayed to delay the gastric fuptilor, these drugs seem to delay the absorption of the blood, painting the buzz.
Although the study's limited sample size and unblinded design limit its applicability to a broader human population, this study provides an important basis and plausible mechanism for previous observations linking GLP1-RAS to better alcohol outcomes, including curbing cravings.These results strongly support the need for larger randomized clinical trials to confirm these effects and explore the potential for repurposing GLP-1 ARS as a new treatment to reduce harmful alcohol consumption.
Download your PDF copy now!
